Trial Profile
Reduced Dose-density of Denosumab for Maintenance Therapy of Unresectable Giant Cell Tumor of Bone: a Multicenter Phase II Study "REDUCE"
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Bone cancer; Giant cell tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms REDUCE
- 15 Jan 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 04 Jan 2021 Status changed from recruiting to discontinued.
- 06 Nov 2020 This trial has been completed in Denmark and France, according to European Clinical Trials Database record.